Masitinib

Active substance
Masitinib
Domain
Oncology and Hematology
Reason of inclusion in Horizonscan Geneesmiddelen
New medicine (specialité)
Main indication
Stomach cancer
Extended indication
Gastro Intestinale Stroma Tumor (GIST)

1. Product

Proprietary name
Masican
Manufacturer
AB Science
Mechanism of action
Tyrosine kinase inhibitor
Route of administration
Oral
Therapeutical formulation
Tablet
Budgetting framework
Intermural (MSZ)

2. Registration

Registration route
Centralised (EMA)
Orphan drug
No
Registration phase
Clinical trials
Additional comments
Wordt onderzocht in veel verschillende indicaties. Eerst in mastocytosis, AML, et cetera Negatieve CHMP-opinie voor mastocytosis en AML in september 2017.

3. Therapeutic value

Therapeutic value
No judgement
Duration of treatment
Not found

4. Expected patient volume per year

Patient volume

0 - 50

Market share is generally not included unless otherwise stated.

References
NKR
Additional comments
In 2016 waren er 50 diagnoses van GIST stadium IV. De kans op een plek in de richtlijn lijkt klein.

5. Expected cost per patient per year

There is currently nothing known about the expected cost.

6. Potential total cost per year

There is currently nothing known about the possible total cost.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

Indication extension
Yes
Indication extensions
Er lopen meerdere fase 3 studies.

9. Other information

There is currently no futher information available.